No Prescription |
 |
 | ||
|
DEFENAC SR Diclofenac |
|
| ||
No Prescription » Prescription Drugs 5 » DEFENAC SR Diclofenac Used to relieve the pain tenderness inflammation (swelling) and stiffness caused by arthritis and gout. It also is used to relieve other pain including menstrual pain and pain after surgery or childbirth. Buy DEFENAC SR Diclofenac and other Prescription Drugs 5 products online at Medstore. 678
About DEFENAC SR Diclofenac: Product Type: Prescription Drugs 5 DEFENAC SR (Diclofenac Voltaren) DEFENAC SR (Diclofenac Voltaren) Diclofenac Voltaren 100mg Tabs 100 (10 x 10) Diclofenac Voltaren DEFENAC SR
View more Prescription Drugs 5 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
